Elite in Cholangiocarcinoma (Bile Duct Cancer)

Mario Scartozzi

Cagliari, IT 
Elite in Cholangiocarcinoma (Bile Duct Cancer)
Cagliari, IT 
OverviewLocationsClinical Research

Overview

Mario Scartozzi practices in Cagliari, Italy. Mr. Scartozzi is rated as an Elite expert by MediFind in the treatment of Cholangiocarcinoma (Bile Duct Cancer). His top areas of expertise are Colorectal Cancer, Cholangiocarcinoma (Bile Duct Cancer), Liver Cancer, Tissue Biopsy, and Liver Embolization.

His clinical research consists of co-authoring 330 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 32 articles in the study of Cholangiocarcinoma (Bile Duct Cancer).

Gender
Male

Locations

Cagliari, Italy
Other Locations
Monserrato, Italy
Milan, Italy
Padova, Italy
Genoa, Italy
Pisa, Italy
Udine, 33100, Italy
Parma, Italy
Ancona, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
PRESERVE 1: A Phase 3 Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: November 26, 2024
Intervention Type: Drug
Study Drug: Trilaciclib
Study Phase: Phase 3
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
A Randomized, Double-blind, Placebo-controlled Phase 2 Study of Paclitaxel in Combination With Reparixin Compared to Paclitaxel Alone as Front-line Therapy for Metastatic Triple- Negative Breast Cancer (FRIDA)
Enrollment Status: Completed
Publish Date: September 16, 2022
Intervention Type: Drug
Study Phase: Phase 2
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
2017-01: Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma
Enrollment Status: Completed
Publish Date: August 06, 2020
Intervention Type: Other
View 2 Less Clinical Trials

329 Total Publications

Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 01, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Scartozzi's expertise for a condition
ConditionClose
View All 8 Advanced Conditions
View All 31 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile